Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines, Inc. (PRAX)
:PRAX
PRAX Analyst Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PRAX Stock 12 Month Forecast
Average Price Target
$301.00
▲(74.64% Upside)
| Highest Price Target$441.00 | Average Price Target$301.00 | Lowest Price Target$232.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$232
Buy
34.61%
Upside
Reiterated
11/06/25
Praxis Precision Medicines: Buy Rating Backed by Accelerated FDA Approval Path and Promising Relutrigine DataValuation and Risks. Our Buy rating and price target of $232 for Praxis are based on the present value of 5.0x our 2035 discounted risk-adjusted revenue estimate of $1.3B. We adjust each pipeline asset for the probability of success: in ET given the positive Phase 3 data, vormatrigine with FOS at 70% given its strong topline Phase 2 data from the RADIANT study, relutrigine and elsunersen at 60% given the early efficacy signal seen in the EMBOLD Cohort 1 and EMBRAVE Part 1, respectively.
Oppenheimer
$250
Buy
45.05%
Upside
Reiterated
11/06/25
LifeSci Capital
$373→$383
Buy
122.22%
Upside
Reiterated
11/06/25
Truist Financial
―
Buy
―
Reiterated
11/05/25
TD Cowen
$251
Buy
45.63%
Upside
Reiterated
11/05/25
Needham
$250
Buy
45.05%
Upside
Reiterated
11/05/25
Positive Outlook for Praxis Precision Medicines: Buy Rating Affirmed Amid Promising FDA Feedback and Strong Efficacy DataWe believe this is a strong signal from the management regarding its confidence in the EMBOLD study as generally the alpha-levels at interim with ~70% information fraction are closer to the 2.5 - 3% range, whereas, in this case, management is allocating the majority of the alpha at the interim analysis suggesting that the study is likely to be successful at the time of interim (expected in 4Q25). In addition, during our conversation with mgt, it noted that the study is already overpowered by a large margin (Cohort 1 with N=15 showed a p value of 0.0354) for the final analysis, plus, the majority of the patients have already moved on to the open-label portion from cohort 2 supporting its confidence in the success of the interim analysis.
JonesTrading
$441
Buy
155.87%
Upside
Reiterated
11/05/25
Praxis Precision Medicines: Buy Rating Affirmed on Promising Phase III Results and Market PotentialWe expect PRAX to continue advancing its differentiated portfolio of epilepsy focused assets and suggest investors closely watch the topline results for vormatrigine in focal onset seizures (1H26). We are encouraged by the accelerated development potential of relutrigine for develomental and epileptic encephalopathies (DEEs), which, per a Type B meeting with the FDA, could see an early 2026 NDA submission if the interim analysis for the ongoing EMBOLD study is positive.
Chardan Capital
$80→$330
Buy
91.47%
Upside
Reiterated
10/17/25
Jefferies
$65→$300
Buy
74.06%
Upside
Reiterated
10/17/25
Deutsche Bank
$65→$280
Buy
62.46%
Upside
Reiterated
10/17/25
Guggenheim
$155→$350
Buy
103.08%
Upside
Reiterated
10/16/25
Robert W. Baird
$76→$275
Buy
59.56%
Upside
Reiterated
10/16/25
Piper Sandler
$270
Buy
56.66%
Upside
Reiterated
10/02/25
Wedbush
$28→$33
Sell
-80.85%
Downside
Reiterated
08/04/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$232
Buy
34.61%
Upside
Reiterated
11/06/25
Praxis Precision Medicines: Buy Rating Backed by Accelerated FDA Approval Path and Promising Relutrigine DataValuation and Risks. Our Buy rating and price target of $232 for Praxis are based on the present value of 5.0x our 2035 discounted risk-adjusted revenue estimate of $1.3B. We adjust each pipeline asset for the probability of success: in ET given the positive Phase 3 data, vormatrigine with FOS at 70% given its strong topline Phase 2 data from the RADIANT study, relutrigine and elsunersen at 60% given the early efficacy signal seen in the EMBOLD Cohort 1 and EMBRAVE Part 1, respectively.
Oppenheimer
$250
Buy
45.05%
Upside
Reiterated
11/06/25
LifeSci Capital
$373→$383
Buy
122.22%
Upside
Reiterated
11/06/25
Truist Financial
―
Buy
―
Reiterated
11/05/25
TD Cowen
$251
Buy
45.63%
Upside
Reiterated
11/05/25
Needham
$250
Buy
45.05%
Upside
Reiterated
11/05/25
Positive Outlook for Praxis Precision Medicines: Buy Rating Affirmed Amid Promising FDA Feedback and Strong Efficacy DataWe believe this is a strong signal from the management regarding its confidence in the EMBOLD study as generally the alpha-levels at interim with ~70% information fraction are closer to the 2.5 - 3% range, whereas, in this case, management is allocating the majority of the alpha at the interim analysis suggesting that the study is likely to be successful at the time of interim (expected in 4Q25). In addition, during our conversation with mgt, it noted that the study is already overpowered by a large margin (Cohort 1 with N=15 showed a p value of 0.0354) for the final analysis, plus, the majority of the patients have already moved on to the open-label portion from cohort 2 supporting its confidence in the success of the interim analysis.
JonesTrading
$441
Buy
155.87%
Upside
Reiterated
11/05/25
Praxis Precision Medicines: Buy Rating Affirmed on Promising Phase III Results and Market PotentialWe expect PRAX to continue advancing its differentiated portfolio of epilepsy focused assets and suggest investors closely watch the topline results for vormatrigine in focal onset seizures (1H26). We are encouraged by the accelerated development potential of relutrigine for develomental and epileptic encephalopathies (DEEs), which, per a Type B meeting with the FDA, could see an early 2026 NDA submission if the interim analysis for the ongoing EMBOLD study is positive.
Chardan Capital
$80→$330
Buy
91.47%
Upside
Reiterated
10/17/25
Jefferies
$65→$300
Buy
74.06%
Upside
Reiterated
10/17/25
Deutsche Bank
$65→$280
Buy
62.46%
Upside
Reiterated
10/17/25
Guggenheim
$155→$350
Buy
103.08%
Upside
Reiterated
10/16/25
Robert W. Baird
$76→$275
Buy
59.56%
Upside
Reiterated
10/16/25
Piper Sandler
$270
Buy
56.66%
Upside
Reiterated
10/02/25
Wedbush
$28→$33
Sell
-80.85%
Downside
Reiterated
08/04/25
Best Analysts Covering Praxis Precision Medicines
1 Month
xxx
Success Rate
11/15 ratings generated profit
Average Return
+10.84%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +10.84% per trade.
3 Months
xxx
Success Rate
10/12 ratings generated profit
Average Return
+69.15%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +69.15% per trade.
1 Year
2 Years
xxx
Success Rate
12/12 ratings generated profit
Average Return
+313.97%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +313.97% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PRAX Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
12
12
15
23
21
Buy
4
5
8
9
10
Hold
10
10
11
8
6
Sell
0
1
1
1
0
Strong Sell
0
0
0
0
0
total
26
28
35
41
37
Each month's total comprises the sum of three months' worth of ratings.
PRAX Financial Forecast
PRAX Stock Forecast FAQ
What is PRAX’s average 12-month price target, according to analysts?
Based on analyst ratings, Praxis Precision Medicines, Inc.’s 12-month average price target is 301.00.
What is PRAX’s upside potential, based on the analysts’ average price target?
Praxis Precision Medicines, Inc. has 74.64% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PRAX a Buy, Sell or Hold?
Praxis Precision Medicines, Inc. has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
What is Praxis Precision Medicines, Inc.’s price target?
The average price target for Praxis Precision Medicines, Inc. is 301.00. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $441.00 ,the lowest forecast is $232.00. The average price target represents 74.64% Increase from the current price of $172.35.
The highest analyst price target is $441.00 ,the lowest forecast is $232.00. The average price target represents 74.64% Increase from the current price of $172.35.
What do analysts say about Praxis Precision Medicines, Inc.?
Praxis Precision Medicines, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of PRAX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.